Modified BCG vaccine boosts TB protection in primates

Tuberculosis remains a leading infectious killer worldwide, and the century-old BCG vaccine only provides variable protection, especially against adult pulmonary TB. Researchers led by Dhiraj Kumar Singh explored a new strategy to make BCG more protective by engaging the immune system in a different way. Instead of changing the bacterial backbone, they modified the vaccine strain to overproduce a small signaling molecule that the innate immune system recognizes. That molecule, cyclic di-AMP, is known to activate the STING pathway, an early-warning system in immune cells that helps coordinate later responses. By making a recombinant BCG that overexpresses cyclic di-AMP, the team sought to stimulate both the innate branch of immunity and the cell-mediated arm that includes T cells, which are critical for controlling Mycobacterium tuberculosis. The work described in the abstract tests whether this targeted boost to innate sensing can translate into stronger protection in a realistic animal model, the non-human primate (NHP) model, which is often used because of its similarity to humans in immune response and disease progression.

The central experimental change reported was a recombinant BCG engineered to overexpress the STING agonist cyclic di-AMP. The abstract emphasizes that this modification makes the small molecule more available to the host immune system, which recognizes it through the STING pathway in innate immune cells. The team tested this recombinant BCG in the non-human primate (NHP) model to evaluate protective efficacy and immune responses. According to the abstract, animals that received the modified vaccine showed significantly improved protection against TB compared with standard approaches. Importantly, the improvement was linked to stronger cell-mediated immune responses, including activity of T cells, which are essential for controlling TB infection. While the abstract does not detail dosing, timelines, or specific assays, it highlights a clear outcome: overexpressing cyclic di-AMP in recombinant BCG enhanced both protective effect and the quality of T cell–mediated immunity in the NHP model.

If the findings described in the abstract hold up under further study, they point to a practical and focused way to improve TB vaccination: harnessing innate immune sensing to shape better T cell responses. By overexpressing a known STING agonist, cyclic di-AMP, within recombinant BCG, the approach deliberately boosts early immune signaling that can set the stage for more effective cell-mediated immunity. This strategy does not require inventing a wholly new vaccine platform; it builds on a widely used vaccine strain and modifies it to enhance immune engagement. The non-human primate (NHP) model result is important because it suggests the improvement is not limited to small-animal studies but can occur in a system closer to humans. Future steps would need to confirm safety, optimal levels of cyclic di-AMP expression, and how durable the enhanced protection is, but the core message is that tuning innate sensors like STING within a live vaccine can materially increase protection against TB and improve T cell responses that are key to long-term control of the disease.